Download presentation
Presentation is loading. Please wait.
Published byAnnice Harrington Modified over 6 years ago
1
New Strategies to Prevent CV Events After Hospital Discharge
2
Program Agenda
3
Crisis and Unmet Needs in Medically Ill Hospitalized Patients
4
Call to Action
5
World Thrombosis Day Facts
6
Absolute Risk of DVT in Hospitalized Patients
7
Lack of Prophylaxis in Medical Patients
8
Cochrane Review of Interventions for Implementation of Hospital VTE Thromboprophylaxis
9
Trials of VTE Prophylaxis in Hospitalized Medical Patients
10
3 Randomized Trials
11
VTE After Hospital Discharge
12
Risk of VTE Extends Post-Hospital Discharge
13
More Than Half of VTE Occurs After 10 Days of Prophylaxis
14
Extended VTE Prophylaxis: 3 Failed Trials Medical Patients
15
ADOPT and MAGELLAN Lessons Learned
16
MARINER Trial Rivaroxaban
17
Summary
18
Prevention of VTE, Stroke, and Rehospitalization for Medically Ill Hospitalized Patients
19
Fatal Saddle PE Autopsy
20
Brigham and Women's Hospital Readmission With NEW VTE Within 30 Days of Hospital Discharge
21
VTE After Hospital Discharge
22
Prevention
23
Betrixaban
24
APEX Study Design
25
Study Design Key Inclusion Criteria
26
Baseline Characteristics Primary Admission Diagnoses
27
Primary Efficacy Endpoint
28
Symptomatic VTE Events
29
Primary Safety Endpoint Major Bleeding
30
Percent Fatal Bleeding and ICH Safety Population
31
FDA: Betrixaban Indication and Use
32
Rate of Stroke or TIA
33
VTE-Related Rehospitalization
34
Primary Efficacy Outcome by History of VTE
35
Summary of Betrixaban
36
Summary Betrixaban Substudies
37
Management of Major Bleeding Among Patients Taking DOACs: State-of-the-Art
38
What Is Major Bleeding?
39
Measures to Treat Significant Bleeding Short of Reversal
40
Reversal Agents
41
Idarucizumab Is BIG
42
Idarucizumab Full Cohort
43
Novel Mechanism of Action Provides Rapid Reversal of Factor Xa Inhibitor Activity Without Prohemostatic or Anticoagulant Effects
44
Andexanet: FDA Approved
45
Time Courses of Anti-Factor Xa Activity Before and After the Administration of Andexanet in Healthy Volunteers: 2016
46
Bleeding Patients 2018: Clinical Hemostatic Efficacy
47
30-Day Assessment in Clinical Trial of Patients who Bled
48
Summary
49
Abbreviations
50
Abbreviations (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.